1 / 23

Pregnancy and SCD

Pregnancy and SCD. Preconception. Hydroxyurea is teratogenic; pregnancy category class D medication. Iron overload should treated before becoming pregnant Chelation therapy should cease upon conception. All patients should be started on 5 mg/day of folic acid

Mercy
Download Presentation

Pregnancy and SCD

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Pregnancy and SCD

  2. Preconception • Hydroxyurea is teratogenic; pregnancy category class D medication. • Iron overload should treated before becoming pregnant • Chelation therapy should cease upon conception. • All patients should be started on 5 mg/day of folic acid • Individuals with chronic hemolysis may require a higher dose.

  3. Ante-partum care • Alloimmunization • Evaluated during the first visit, at which time the risk of alloimmunization is high • Re-evaluated at weeks 24–28, and during delivery, if negative at the first visit • Thromboembolism • All hospitalized patients for an acute medical condition require thromboembolism prophylaxis with low molecular-weight or fractionated heparin, unless such treatment is contra-indicated

  4. Ante-partum care • Preeclampsia • Low-dose aspirin after 12 weeks' gestation may decrease the risk of preeclampsia, preterm birth, and poor pregnancy outcomes; however increase bleeding and placental abruption.

  5. Ante-partum care: Transfusion in pregnancy • There is no consensus on transfusions in pregnancy. • In a meta-analysis of 1291 patients: Blood 2015;126:2424–2435 • Prophylactic transfusions decreased maternal mortality (odds ratio [OR] 0.23) • Vaso-occlusive pain episodes (OR 0.26) • Pulmonary embolism (OR 0.07) • Perinatal mortality (OR 0.43) • Neonatal death (OR 0.2), and preterm birth (OR 0.59) • Low event rates & a variety of transfusion goals

  6. Ante-partum care: Transfusion in pregnancy • Only RCT; prophylactic vs on-demand transfusions: N Engl J Med 1988;319:1447–1452 • Lower vaso-occlusive pain crises (relative risk 0.28) • No significant difference in perinatal mortality, intrauterine fetal demise, or neonatal death • Study was underpowered and the rate of events was small.

  7. Ante-partum care: Transfusion in pregnancy • Reasonable approach • Prophylactic exchange transfusions, especially in the third trimester, every 3–4 weeks • Chronic organ dysfunction • “History” of acute chest syndrome • Frequent pain crises • A goal hemoglobin of 10 g/dL and HbS <30%

  8. Intra-partum • Delivery is recommended at gestational weeks 38–40 • The general medical indications for cesarean section patients are valid in those with SCD • Local-regional anesthesia preferred because it decreases the risk of sickling complications. • If patients undergo cesarean section they should be transfused to a goal hemoglobin of 10 g/dL.

  9. Intra-partum • Thromboprophylaxis is recommended - low-molecular-weight heparin, or heparin. • LMWH/heparin should be discontinued 24 hr prior to delivery and recommenced 12 h thereafter.

  10. Post-partum • Prophylaxis with LMWH/heparin should be maintained to 6 weeks after cesarean section. • Hydroxyurea should not be used during lactation as the drug passes into breast milk

  11. Perioperative management in SCD

  12. Preoperative transfusion • Cooperative Study of Sickle Cell Diseases. Blood. 1995;86(10):3676-84. • In 717 patients undergoing surgical procedures • The combined incidence of all sickle cell-related complications postoperatively was significantly lower in those who had preoperative transfusion compared to those who did not have transfusion. • Similar results were demonstrated in individuals with sickle hemoglobin C (HbSC) disease

  13. Preoperative transfusion • A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease. The Preoperative Transfusion in Sickle Cell Disease Study Group. N Engl J Med. 1995;333(4):206-13. 403 • Compared the use of simple transfusion with a hemoglobin (Hb) goal of 10 g/dL preoperatively to the use of exchange transfusion to bring the HbS ≤30 percent. • No statistically significant reduction in the incidence of perioperative complications was seen between the two arms of the study

  14. Preoperative transfusion • The transfusion alternatives preoperatively in sickle cell disease (TAPS) study: a randomised, controlled, multicentre clinical trial. Lancet. 2013;381(9870):930-8. • Randomized to either no preoperative transfusion or preoperative transfusion • Patients undergoing low risk (e.g., adenoidectomy, inguinal hernia repair) • Medium-risk (e.g., cholecystectomy, joint replacement) procedures • The transfusion goal was to raise the hemoglobin to 10.0 g/dL. • In patients with preoperative hemoglobin levels of 9.0 g/dL or higher, a partial exchange transfusion was done. • The study was closed early due to significantly more complications in the medium-risk, no preoperative transfusion arm than in the medium-risk transfusion arm (10/33 vs. 1/34).

  15. Preoperative transfusion • 2014 NIH Expert Panel Report • Strong Recommendation, Moderate-Quality Evidence • Transfuse RBCs to bring the hemoglobin level to 10 g/dL prior to undergoing a surgical procedure involving general anesthesia.

  16. Stroke management in SCD

  17. HbSS have a high prevalence (4.01%) and incidence (0.61 per 100 patient years) of cerebrovascular accidents • Ischemic strokes have a bimodal distribution, being more common in children and older adults, and lowest in adults aged 20 to 29 years • Risk factors: prior TIA, low steady-state hemoglobin, recent episode of acute chest syndrome (ACS), and elevated systolic blood pressure • Hemorrhagic stroke most frequent in the 20- to 29-year age group. • Risk factors: low steady-state Hb and high leukocyte count

  18. Acute focal neurologic deficits differential diagnosis • Acute arterial stroke (ischemic infarct) • Typically obtain an MRI of the brain to distinguish between a stroke and a TIA • Stroke: strong consideration is given for lifelong regular transfusion therapy • TIA: regular blood transfusion therapy only in the presence of other risk factors • Prior TIAs • Abnormal transcranial Doppler ultrasound measurements • Cerebral vasculopathy • Presence of silent cerebral infarcts

  19. Acute focal neurologic deficits differential diagnosis • Hemorrhagic stroke • Most common neurologic event in adults with SCD • No etiology for hemorrhagic stroke is identified in most cases • Subarachnoid hemorrhage is the most common etiology • Intracranial aneurysm • No evidence-based approach • Seizures • Hemiplegic migraine

  20. Acute focal neurologic deficits differential diagnosis • Posterior reversible encephalopathy syndrome (PRES) • Headache, seizure, visual disorders, and AMS, and supported by imaging findings that show parietal and occipital involvement of the brain, likely resulting from vasogenic edema • Can be associated with ACS • Central sinus venous thrombosis (CSVT) • MRV is the preferred initial imaging

  21. Acute care • Labs • CBC, reticulocyte count • Type and cross match, HbS% • Prothrombin time, activated partial thromboplastin time • Basic metabolic profile • Imaging • MRI/MRV preferred (to evaluate for CSVT) • MRI preferred over a brain CT to detect both hemorrhage and cerebral infarct

  22. Acute care • Emergent exchange blood transfusion therapy preferred • Or simple transfusion, followed by exchanged transfusion • Subacute care • Repeat the MRI of the brain within 14 to 30 days after initial stroke

  23. Long-term care • Secondary prevention • Exchange transfusion preferred (less iron load) • Hydroxyurea • Hematopoietic stem cell transplant (HSCT) for secondary stroke prevention • May be best option in children

More Related